Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Comment
  • Published:

Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity

Nature Medicine volume 30, pages 22–25 (2024)Cite this article

Subjects

GLP-1 receptor agonists are effective treatments for obesity but are less accessible worldwide than pharmacological treatments for diabetes, reflecting biases and lack of education, and perpetuating health inequalities.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Michaelidou, M., Pappachan, J. M. & Jeeyavudeen, M. S. World J. Diabetes 14, 396–411 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  2. Gomez, G. & Stanford, F. C. Int. J. Obes. 42, 495–500 (2018).

    Article  CAS  Google Scholar 

  3. Bessesen, D. H. & Van Gaal, L. F. Lancet Diabetes Endocrinol. 6, 237–248 (2018).

    Article  PubMed  Google Scholar 

  4. Washington, T. B. et al. Gastroenterol Clin North Am 52, 429–441 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Nauck, M. A. & Meier, J. J. Diabetes Obes. Metab. 20, 5–21 (2018).

    Article  CAS  PubMed  Google Scholar 

  6. Drucker, D. J. Mol. Metab. 57, 101351 (2022).

    Article  CAS  PubMed  Google Scholar 

  7. Chatterjee, S., Khunti, K. & Davies, M. J. Lancet 389, 2239–2251 (2017).

    Article  CAS  PubMed  Google Scholar 

  8. ElSayed, N. A. et al. Diabetes Care 46(Suppl. 1), S5–S9 (2022).

    PubMed Central  Google Scholar 

  9. Grunvald, E. et al. Gastroenterology 163, 1198–1225 (2022).

    Article  CAS  PubMed  Google Scholar 

  10. Uerlich, M. F., Yumuk, V., Finer, N., Basdevant, A. & Visscher, T. L. Obes. Facts 9, 273–283 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  11. Meikle, A. et al. Semaglutide for managing overweight and obesity: technology appraisal guidance (UK NICE, 2023).

  12. Cohen, J. Forbes (11 June 2023).

  13. Kyle, T. K. & Stanford, F. C. Obesity 24, 1832 (2016).

    Article  PubMed  Google Scholar 

  14. Jannah, N., Hild, J., Gallagher, C. & Dietz, W. Obesity 26, 1834–1840 (2018).

    Article  PubMed  Google Scholar 

  15. Sumarsono, A. et al. Diabetes Care 43, 2684–2690 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Author notes

  1. These authors contributed equally: Stephanie W. Waldrop, Veronica R. Johnson.

Authors and Affiliations

  1. University of Colorado School of Medicine–Anschutz Medical Campus, Department of Pediatrics, Section on Nutrition and Lifestyle Medicine, Nutrition Obesity Research Center at the University of Colorado (CUNORC), Aurora, CO, USA

    Stephanie W. Waldrop

  2. Northwestern University Feinberg School of Medicine, Department of Medicine, Division of General Internal Medicine, Chicago, IL, USA

    Veronica R. Johnson

  3. Massachusetts General Hospital, Massachusetts General Hospital Weight Center, Department of Medicine–Division of Endocrinology-Neuroendocrine, Department of Pediatrics–Division of Endocrinology, Nutrition Obesity Research Center at Harvard (NORCH), Boston, MA, USA

    Fatima Cody Stanford

Authors
  1. Stephanie W. Waldrop
    View author publications

    Search author on:PubMed Google Scholar

  2. Veronica R. Johnson
    View author publications

    Search author on:PubMed Google Scholar

  3. Fatima Cody Stanford
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Stephanie W. Waldrop.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Waldrop, S.W., Johnson, V.R. & Stanford, F.C. Inequalities in the provision of GLP-1 receptor agonists for the treatment of obesity. Nat Med 30, 22–25 (2024). https://doi.org/10.1038/s41591-023-02669-x

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41591-023-02669-x

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing